Replies to post #689045 on NorthWest Biotherapeutics Inc (NWBO)

[dstock07734]

biosectinvestor,

I went through all the trials on cancer SWOG was running. It seems like that SWOG is playing with various combinations of the different drugs from all the BPs. I haven't seen any extraordinary results from any of these trials. I am really curious about the objectives of these trials. Is SWOG trying to find some combinations that are really working? It seems like SWOG is trying to convince people that none of these combinations are working.

S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct Therapy Duration (DRAMMATIC)
https://classic.clinicaltrials.gov/ct2/show/NCT04071457?recrs=ab&lead=swog&draw=2&rank=26

Daratumumab -- Janssen Biotech, Inc.
Lenalidomide -- Bristol Myers Squibb


Ramucirumab and Paclitaxel or FOLFIRI in Advanced Small Bowel Cancers
https://classic.clinicaltrials.gov/ct2/show/NCT04205968?recrs=ab&lead=swog&draw=2&rank=24

Paclitaxel -- Bristol-Myers Squibb
Ramucirumab -- Eli Lilly


Comparing the Outcome of Immunotherapy-Based Drug Combination Therapy With or Without Surgery to Remove the Kidney in Metastatic Kidney Cancer, the PROBE Trial (PROBE)
https://classic.clinicaltrials.gov/ct2/show/NCT04510597?recrs=ab&lead=swog&draw=2&rank=21

Nivolumab -- Bristol-Myers Squibb
Pembrolizumab -- Merck
Avelumab -- Merck KGaA and Pfizer


A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases
https://classic.clinicaltrials.gov/ct2/show/NCT04511013?recrs=ab&lead=swog&draw=2&rank=20

Binimetinib -- Pfizer
Encorafenib -- Pfizer
Ipilimumab -- Bristol-Myers Squibb
Nivolumab -- Bristol-Myers Squibb


Testing the Use of Targeted Treatment (AMG 510) for KRAS G12C Mutated Advanced Non-squamous Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)
https://classic.clinicaltrials.gov/ct2/show/NCT04625647?recrs=ab&lead=swog&draw=2&rank=19

Sotorasib -- Amgen

Testing Sacituzumab Govitecan Therapy in Patients With HER2-Negative Breast Cancer and Brain Metastases
https://classic.clinicaltrials.gov/ct2/show/NCT04647916?recrs=ab&lead=swog&draw=2&rank=18

Sacituzumab Govitecan -- Gilead

Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors
https://classic.clinicaltrials.gov/ct2/show/NCT05040360?recrs=ab&lead=swog&draw=2&rank=15

Capecitabine -- Roche
Temozolomide -- Merck


Testing the Use of Targeted Treatment for RET Positive Advanced Non-small Cell Lung Cancer
https://classic.clinicaltrials.gov/ct2/show/NCT05364645?recrs=ab&lead=swog&draw=2&rank=14

Pemetrexed -- Eli Lilly
Selpercatinib -- Eli Lilly


Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment
https://classic.clinicaltrials.gov/ct2/show/NCT05561387?recrs=ab&lead=swog&draw=2&rank=12

Bortezomib -- Takeda
Daratumumab and Hyaluronidase-fihj -- Johnson & Johnson
Lenalidomide -- Bristol-Myers Squibb

Ramucirumab Plus Pembrolizumab vs Usual Care for Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer Following Immunotherapy, Pragmatica-Lung Study
https://classic.clinicaltrials.gov/ct2/show/NCT05633602?recrs=ab&lead=swog&draw=2&rank=10

Pembrolizumab -- Merck
Ramucirumab -- Eli Lilly


Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
https://classic.clinicaltrials.gov/ct2/show/NCT05633615?recrs=ab&lead=swog&draw=2&rank=9

Axicabtagene Ciloleucel -- Gilead
Lisocabtagene Maraleucel -- Bristol-Myers Squibb
Tisagenlecleucel -- Novartis
Polatuzumab Vedotin -- Roche
Mosunetuzumab -- Roche


Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
https://classic.clinicaltrials.gov/ct2/show/NCT05642572?recrs=ab&lead=swog&draw=2&rank=8

Capmatinib -- Novartis
Osimertinib -- AstraZeneca
Ramucirumab -- Eli Lilly

Carboplatin Chemotherapy Before Surgery for People With High-Risk Prostate Cancer and an Inherited BRCA1 or BRCA2 Gene Mutation
https://classic.clinicaltrials.gov/ct2/show/NCT05806515?recrs=ab&lead=swog&draw=2&rank=6

Carboplatin -- Bristol-Myers Squibb


Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment
https://classic.clinicaltrials.gov/ct2/show/NCT05890352?recrs=ab&lead=swog&draw=2&rank=5

Lenalidomide -- Bristol-Myers Squibb
Tafasitamab -- Incyte
Tazemetostat -- Ipsen
Zanubrutinib -- BeiGene


Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer
https://classic.clinicaltrials.gov/ct2/show/NCT05929768?recrs=ab&lead=swog&draw=2&rank=4

Carboplatin -- Bristol-Myers Squibb
Paclitaxel -- Bristol-Myers Squibb
Pembrolizumab -- Merck

Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
https://classic.clinicaltrials.gov/ct2/show/NCT06031688?recrs=ab&lead=swog&draw=2&rank=2
Ramucirumab -- Eli Lilly
Tepotinib -- Merck KGaA


Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)
https://classic.clinicaltrials.gov/ct2/show/NCT06116682?recrs=ab&lead=swog&draw=2&rank=1

Amivantamab -- Janssen and Genmab

Targeted Treatment for RET Fusion-Positive Advanced Non-Small Cell Lung Cancer (A LUNG-MAP Treatment Trial)
https://classic.clinicaltrials.gov/ct2/show/NCT04268550?recrs=bd&lead=swog&draw=2&rank=6
Selpercatinib -- Eli Lilly


Testing the Use of Combination Immunotherapy Treatment (N-803 [ALT-803] Plus Pembrolizumab) Against the Usual Treatment for Advanced Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)
https://classic.clinicaltrials.gov/ct2/show/NCT05096663?recrs=bd&lead=swog&draw=2&rank=4

Nogapendekin Alfa -- ImmunityBio
Pembrolizumab -- Merck
Ramucirumab -- Eli Lilly


Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)
https://classic.clinicaltrials.gov/ct2/show/NCT06116682?recrs=bd&lead=swog&draw=2&rank=1

Amivantamab -- Janssen and Genmab

Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
https://classic.clinicaltrials.gov/ct2/show/NCT06031688?recrs=bd&lead=swog&draw=2&rank=2

Ramucirumab -- Eli Lilly
Tepotinib -- Merck KGaA